The REAnimation Low Immune Status Markers (REALISM) project: A protocol for broad characterisation and follow-up of injury-induced immunosuppression in intensive care unit (ICU) critically ill patients

BMJ Open

Volumn 7, Issue 6, 2017, Pages

  Rol, Mary Luz ^a,b   Venet, Fabienne ^b,c   Rimmele, Thomas ^b,c   Moucadel, Virginie ^d   Cortez, Pierre ^e   Quemeneur, Laurence ^f   Gardiner, David ^h   Griffiths, Andrew ^g   Pachot, Alexandre ^b,d   Textoris, Julien ^b,c,d   Monneret, Guillaume ^b,c  

^a BIOASTER   (France)

^b University of Lyon EA 7426 Pathophysiology of Injury Induced Immunosuppression PI3   (France)

^c UNIVERSITÉ LYON 1   (France)

^d BIOMÉRIEUX   (France)

^e SANOFI   (France)

^f SANOFI PASTEUR   (France)

^g PSL RESEARCH UNIVERSITY   (France)

^h GLAXOSMITHKLINE   (United States)

Author keywords

Adaptive immunity; Biomarkers; Healthcare associated infections; Injury induced immunosuppression; Innate immunity; Intensive care unit

Indexed keywords

BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR; PHYTOHORMONE;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; BLOOD; BURN; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INJURY; INJURY INDUCED IMMUNOSUPPRESSION; INJURY SEVERITY; INNATE IMMUNITY; INTENSIVE CARE UNIT; LONGITUDINAL STUDY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MAJOR SURGERY; MALE; MITOGENICITY; MONOCYTE; MORTALITY; OBSERVATIONAL STUDY; PATIENT SAFETY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY; SECONDARY INFECTION; SEPTIC SHOCK; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; AGED; CELL CULTURE; CELL PROLIFERATION; CLINICAL STUDY; CRITICAL ILLNESS; DRUG EFFECTS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; SURGERY; VERY ELDERLY; YOUNG ADULT;

ADAPTIVE IMMUNITY; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CELL PROLIFERATION; CELLS, CULTURED; CLINICAL STUDIES AS TOPIC; CRITICAL ILLNESS; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; IMMUNOPHENOTYPING; INTENSIVE CARE UNITS; LIPOPOLYSACCHARIDES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PLANT GROWTH REGULATORS; PROSPECTIVE STUDIES; RESEARCH DESIGN; SHOCK, SEPTIC; SURGICAL PROCEDURES, OPERATIVE; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; WOUNDS AND INJURIES; YOUNG ADULT;

EID: 85021089436     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2016-015734     Document Type: Article

References (31)

1. Jawad I, Lukši I, Rafnsson SB. Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality. J Glob Health 2012; 2: 4.
2. Vincent JL, Marshall JC, Namendys-Silva SA, et al. Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit. Lancet Respir Med 2014; 2: 380-6.
3. Walkey AJ, Lagu T, Lindenauer PK. Trends in sepsis and infection sources in the United States. A population-based study. Ann Am Thorac Soc 2015; 12: 216-20.
4. Seymour CW, Rea TD, Kahn JM, et al. Severe sepsis in pre-hospital emergency care: analysis of incidence, care, and outcome. Am J Respir Crit Care Med 2012; 186: 1264-71.
5. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic shock (Sepsis-3). JAMA 2016; 315: 801.
6. Angus DC, van der Poll T, Sepsis S, et al. Severe sepsis and septic shock. N Engl J Med 2013; 369: 840-51.
7. Cohen J, Vincent JL, Adhikari NK, et al. Sepsis: a roadmap for future research. Lancet Infect Dis 2015; 15: 581-614.
8. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013; 13: 862-74.
9. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013; 13: 260-8.
10. Delsing CE, Gresnigt MS, Leentjens J, et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect Dis 2014; 14: 166.
11. Venet F, Lukaszewicz AC, Payen D, et al. Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. Curr Opin Immunol 2013; 25: 477-83.
12. Meisel C, Schefold JC, Pschowski R, et al. Granulocytemacrophage colony-stimulating factor to reverse sepsisassociated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009; 180: 640-8.
13. Gentile LF, Cuenca AG, Efron PA, et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg 2012; 72: 1491-501.
14. Angele MK, Chaudry IH. Surgical trauma and immunosuppression: pathophysiology and potential immunomodulatory approaches. Langenbecks Arch Surg 2005; 390: 333-41.
15. Kimura F, Shimizu H, Yoshidome H, et al. Immunosuppression following surgical and traumatic injury. Surg Today 2010; 40: 793-808.
16. Timmermans K, Kox M, Vaneker M, et al. Plasma levels of dangerassociated molecular patterns are associated with immune suppression in trauma patients. Intensive Care Med 2016; 42: 551-61.
17. Gossez M, Malcus C, Demaret J, et al. Evaluation of a novel automated volumetric flow cytometer for absolute CD4+ T lymphocyte quantitation. Cytometry B Clin Cytom 2016: n/a.
18. http://www.clinicaltrial. gov/.
19. Duffy D, Rouilly V, Libri V, et al. Functional analysis via standardized whole-blood stimulation systems defines the boundaries of a healthy immune response to complex stimuli. Immunity 2014; 40: 436-50.
20. Poujol F, Monneret G, Friggeri A, et al. Flow cytometric evaluation of lymphocyte transformation test based on 5-ethynyl-2'deoxyuridine incorporation as a clinical alternative to tritiated thymidine uptake measurement. J Immunol Methods 2014; 415: 71-9.
21. Baker SP, O'Neill B, Haddon W, et al. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma 1974; 14: 187-96.
22. European Centre for Disease Prevention and Control. Point prevalence survey of healthcareassociated infections and antimicrobial use in european acute care hospitals: ECDC, 2012.
23. van Vught LA, Klein Klouwenberg PM, Spitoni C, et al. Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA 2016; 315: 1469-79.
24. Demaret J, Venet F, Friggeri A, et al. Marked alterations of neutrophil functions during sepsis-induced immunosuppression. J Leukoc Biol 2015; 98: 1081-90.
25. Venet F, Chung CS, Kherouf H, et al. Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med 2009; 35: 678-86.
26. Döcke WD, Höflich C, Davis KA, et al. Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem 2005; 51: 2341-7.
27. Horowitz GL, Altaie S, Boyd JC, et al. CLSI C28-A3 defining, establishing and verifying reference intervals in the Clinical Laboratory Approved Guideline, 2008.
28. Fine JP, Gray RJ. A proportional hazards Model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
29. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22: 707-10.
30. Le Gall JR, Lemeshow S, Saulnier F. A New Simplified Acute Physiology Score (SAPS II) based on a European/North American Multicenter study. JAMA 1993; 270: 2957-63.
31. TranSMART. http://transmartfoundation.org/.